XXXiaoyu Xu

Xiaoyu Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoyu Xu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multifunctional Pd Single-Atom Nanozyme for Enhanced Cascade Chemodynamic Therapy of Chronic Wounds

    by Xiaoyu Xu, Juyang Zhang, Xinye Wang, Huiyi Fang, Shaoze Shi, Fan Wu, Ninglin Zhou, Jian Shen, Baohong Sun


  • Open Access

    Network Pharmacology and Molecular Docking-Based Strategy to Investigate the Multitarget Mechanisms of Shenqi Yizhi Granule on Alzheimer’s Disease

    by Linshuang Wang, Xiaoyu Xu, Zikang Wang, Qian Chen, Xiaodie Wei, Jingfan Xue, Zhanjun Zhang, Miao Wang, Yanping Li, Junying Zhang, et al.

    Background. Traditional Chinese herbal medicine draws more attention to explore an effective therapeutic strategy for Alzheimers disease (AD). Shenqi Yizhi granule (SQYG), a Chinese herbal recipe, has been applied to ameliorate cognitive impairment in mild-to-moderate AD patients. However, the overall molecular mechanism of SQYG in treating AD has not been clarified. Objective. This study aimed to investigate the molecular mechanism of SQYG on AD using an integration strategy of network pharmacology and molecular docking. Methods. The active compounds of SQYG and common targets between SQYG and AD were screened from databases. The herb-compound network, compound-target network, and protein-protein interaction network were constructed. The enrichment analysis of common targets and molecular docking were performed. Results. 816 compounds and 307 common targets between SQYG and AD were screened. KEGG analysis revealed that common targets were mainly enriched in lipid metabolism, metal ion metabolism, IL-17 signaling pathway, GABA receptor signaling, and neuroactive ligand-receptor interaction. Molecular docking analysis showed high binding affinity between ginsenoside Rg1 and Aβ1–42, tanshinone IIA and BACE1, baicalin, and AchE. Conclusions. The therapeutic mechanisms of SQYG on AD were associated with regulating lipid metabolism, metal ion metabolism, IL-17 signaling pathway, and GABA receptor signaling. Ginsenoside Rg1, tanshinone IIA, baicalin, astragaloside IV, and folic acid may play an important role in AD treatment.


  • Open Access

    Decoding the Mechanism of CheReCunJin Formula in Treating Sjögren’s Syndrome Based on Network Pharmacology and Molecular Docking

    by Xiaoyu Xu, Linshuang Wang, Qian Chen, Zikang Wang, Xun Pan, Xike Peng, Miao Wang, Dongfeng Wei, Yanping Li, Bin Wu

    Background. Sjögrens syndrome (SS) is a chronic autoimmune disease characterized by progressive oral and ocular dryness that correlates poorly with autoimmune damage to the glands. CheReCunJin (CRCJ) formula is a prescription formulated according to the Chinese medicine theory for SS treatment. Objective. This study aimed to explore the underlying mechanisms of CRCJ against SS. Methods. The databases, including Traditional Chinese Medicine System Pharmacology, Encyclopedia of Traditional Chinese Medicine, Bioinformatics Analysis Tool for the molecular mechanism of Traditional Chinese Medicine, and Traditional Chinese Medicine Integrated Databases, obtained the active ingredients and predicted targets of CRCJ. Then, DrugBank, Therapeutic Target Database, Genecards, Comparative Toxicogenomics Database, and DisGeNET disease databases were used to screen the predicted targets of SS. Intersected targets of CRCJ and SS were visualized by using Venn diagrams. The overlapping targets were uploaded to the proteinprotein interaction network analysis search tool. Cytoscape 3.8.2 software constructed a compound-targets-disease network. Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analyses characterized potential targets biological functions and pathways. AutoDock Vina 1.1.2 software was used to research and verify chemical effective drug components and critical targets. Results. From the database, we identified 878 active components and 2578 targets of CRCJ, and 827 SS-related targets. 246 SS-related genes in CRCJ were identified by intersection analysis, and then ten hub genes were identified as crucial potential targets from PPI, including ALB, IL-6, TNF, INS, AKT1, IL1B, VEGFA, TP53, JUN, and TLR4. The process of CRCJ action against SS was mainly involved in human cytomegalovirus infection and Th17 cell differentiation, as well as the toll-like receptor signaling and p53 signaling pathways. Molecular docking showed that the bioactive compounds of CRCJ had a good binding affinity with hub targets. Conclusions. The results showed that CRCJ could activate multiple pathways and treat SS through multiple compounds and targets. This study lays a foundation for better elucidation of the molecular mechanism of CRCJ in the treatment of SS, and also provides basic guidance for future research on Chinese herbal compounds.